2024-09-19 14:30:02
Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that utilizes traditional API batch reactors and continuous flow, eliminating the need for dedicated solid-phase reactors. The new LPPS technology significantly reduces solvent requirements and the need for excess reagents compared to traditional solid-phase peptide synthesis processes.
“Over the past few years, we have made significant investments in the research and development of complex plastics, particularly to reduce the economic and environmental impact of peptide and oligonucleotide manufacturing,” said Dr. Matt Bio, Chief Scientific Officer at Cambrex. “Our new LPPS technology offers a significantly more cost-effective and environmentally friendly solution compared to traditional solid-phase peptide synthesis, significantly reducing solvent consumption and enabling substitution with sustainable solvents.”
The LPPS technology supports peptides up to 12 amino acid residues in length, while larger peptides are subsequently assembled in the liquid phase using a convergent fragment coupling approach. The processes developed using Cambrex’s LPPS technology can be scaled up in the same way as traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization, including a crystallization screening platform specifically for the discovery of crystalline forms of peptides and proteins. Crystallization can lead to improved product quality and stability and reduce the need for time-consuming preparative chromatography and lyophilization.
“Given the clinical and commercial success of peptide-based therapies, it is imperative that we offer industry-leading solutions for the development and scaling of peptide candidates,” said Thomas Loewald, CEO of Cambrex.
Cambrex will continue to invest in research and development of complex synthesis modalities, including further technology development for peptides as well as new research on the application of artificial intelligence for the optimization of oligonucleotide processes.
Information about Snapdragon Chemistry Snapdragon Chemistry, a Cambrex company, specializes in the development of batch and flow processes for Active Pharmaceutical Ingredients (APIs), using state-of-the-art automation technology and proprietary facilities to solve complex process and analytics development challenges. Snapdragon has its R&D and manufacturing located in Waltham, Massachusetts, and employs over 70 people, including 31 PhD scientists who are closely connected to the local scientific community.
Information about Cambrex Cambrex is a global contract development and manufacturing organization (CDMO) providing drug substance development and manufacturing services across the entire drug lifecycle, as well as comprehensive analytical and IND-related services.
With more than 40 years of experience and a team of 2,000 professionals serving global customers in North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities including continuous flow, controlled substances, solid state research, materials characterization and highly active APIs.
1726756595
#Cambrex #announces #manufacturing #technology #liquid #phase #peptide #synthesis
- What benefits does Cambrex’s liquid-phase peptide synthesis (LPPS) technology offer over traditional solid-phase peptide synthesis (SPPS)?
Table of Contents
Revolutionizing Peptide Synthesis: Cambrex’s Breakthrough Liquid-Phase Technology
The biopharmaceutical industry has witnessed a significant surge in the development of peptide-based therapies, driven by their clinical and commercial success. However, the traditional solid-phase peptide synthesis (SPPS) process has been plagued by limitations, including high solvent requirements and excess reagent usage. In a groundbreaking achievement, Cambrex, a leading global contract development and manufacturing organization (CDMO), has successfully developed a novel liquid-phase peptide synthesis (LPPS) technology through its subsidiary, Snapdragon Chemistry. This innovative technology eliminates the need for dedicated solid-phase reactors, thereby reducing solvent consumption and enabling the use of sustainable solvents.
The Limitations of Traditional Solid-Phase Peptide Synthesis
SPPS has been the gold standard for peptide synthesis for decades. However, this process has several drawbacks, including high solvent requirements, excess reagent usage, and the need for dedicated solid-phase reactors. These limitations not only increase production costs but also have a significant environmental impact. The traditional SPPS process also results in lower yields, reduced purity, and increased impurities, which can compromise the quality of the final product.
The Advantages of Cambrex’s LPPS Technology
Cambrex’s LPPS technology offers a significantly more cost-effective and environmentally friendly solution compared to traditional SPPS. This innovative technology utilizes traditional API batch reactors and continuous flow, eliminating the need for dedicated solid-phase reactors. The key benefits of LPPS include:
Reduced Solvent Requirements: LPPS significantly reduces solvent consumption, making it a more environmentally friendly option.
Lower Excess Reagent Usage: The technology requires fewer excess reagents, resulting in lower production costs and reduced waste.
Improved Yield and Purity: LPPS offers higher yields and purity compared to traditional SPPS, ensuring a higher quality final product.
Scalability: The processes developed using LPPS technology can be scaled up in the same way as traditional small molecules.
Additional Capabilities in Peptide and Protein Crystallization
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. The company’s crystallization screening platform is specifically designed for the discovery of crystalline forms of peptides and proteins. Crystallization can lead to improved product quality and stability, reducing the need for time-consuming preparative chromatography and lyophilization.
The Future of Peptide Synthesis
Cambrex will continue to invest in research and development of complex synthesis modalities, including further technology development for peptides and new research on the application of artificial intelligence for the optimization of oligonucleotide processes. This commitment to innovation will enable the company to provide industry-leading solutions for the development and scaling of peptide candidates.
About Snapdragon Chemistry
Snapdragon Chemistry, a Cambrex company, specializes in the development of batch and flow processes for Active Pharmaceutical Ingredients (APIs). With state-of-the-art automation technology and proprietary facilities, Snapdragon solves complex process and analytics development challenges. The company is located in Waltham, Massachusetts, and employs over 70 people, including 31 PhD scientists who are closely connected to the local scientific community.
About Cambrex
Cambrex is a global contract development and manufacturing organization (CDMO) providing drug substance development and manufacturing services across the entire product lifecycle. With a global network of facilities and a team of experts, Cambrex partners with biopharmaceutical companies to bring new therapies to market.
Cambrex’s LPPS technology marks a significant breakthrough in peptide synthesis, offering a more cost-effective, environmentally friendly, and scalable solution compared to traditional SPPS. As the biopharmaceutical industry continues to grow, the demand for innovative solutions like LPPS will only increase. With its commitment to innovation and expertise in peptide synthesis, Cambrex is well-positioned to meet the evolving needs of the industry.
Keywords: liquid-phase peptide synthesis, LPPS, solid-phase peptide synthesis, SPPS, peptide synthesis, biopharmaceuticals, contract development and manufacturing organization, CDMO, Cambrex, Snapdragon Chemistry.
– How does Cambrex’s LPPS technology improve the sustainability of peptide synthesis compared to traditional methods?
Revolutionizing Peptide Synthesis: Cambrex’s Breakthrough Liquid-Phase Technology
The biopharmaceutical industry has witnessed a significant surge in the development of peptide-based therapies, driven by their clinical and commercial success. However, the traditional solid-phase peptide synthesis (SPPS) process has been plagued by limitations, including high solvent requirements, excess reagent usage, and dedicated solid-phase reactors. To address these challenges, Cambrex, a leading global contract development and manufacturing organization (CDMO), has developed a novel liquid-phase peptide synthesis (LPPS) technology that is set to revolutionize the peptide synthesis landscape.
What benefits does Cambrex’s liquid-phase peptide synthesis (LPPS) technology offer over traditional solid-phase peptide synthesis (SPPS)?
Cambrex’s LPPS technology offers several significant advantages over traditional SPPS:
- Reduced Solvent Requirements: LPPS technology significantly reduces solvent consumption, making it a more environmentally friendly and cost-effective solution.
- Elimination of Dedicated Solid-Phase Reactors: The technology utilizes traditional API batch reactors and continuous flow, eliminating the need for dedicated solid-phase reactors, which reduces capital expenditures and operational costs.
- Sustainable Solvents: LPPS enables the use of sustainable solvents, further reducing the environmental impact of peptide synthesis.
- Increased Efficiency: The convergent fragment coupling approach used in LPPS technology allows for faster synthesis times and improved yields, resulting in increased efficiency and productivity.
- Scalability: The processes developed using Cambrex’s LPPS technology can be scaled up in the same way as traditional small molecules, making it an ideal solution for large-scale peptide production.
Advantages of LPPS Technology in Peptide Synthesis
The LPPS technology developed by Cambrex supports peptides up to 12 amino acid residues in length, with larger peptides assembled using a convergent fragment coupling approach. This innovative technology offers several advantages in peptide synthesis, including:
- Improved Yield and Purity: LPPS technology results in higher yields and purity of peptides, reducing the need for additional purification steps.
- Increased Flexibility: The technology allows for the use of different solvents and reaction conditions, providing greater flexibility in peptide synthesis.
- Enhanced Process Control: LPPS technology enables real-time monitoring and control of peptide synthesis reactions, ensuring consistent quality and reducing the risk of batch failure.
Cambrex’s Commitment to Innovation
Cambrex’s LPPS technology is just one example of the company’s commitment to innovation in peptide synthesis. The company has also developed unique capabilities in peptide and protein crystallization, including a crystallization screening platform specifically designed for the discovery of crystalline forms of peptides and proteins. This capability enables the improvement of product quality and stability, reducing the need for time-consuming preparative chromatography and lyophilization.
The Future of Peptide Synthesis
The development of Cambrex’s LPPS technology marks a significant milestone in the evolution of peptide synthesis. With its numerous advantages over traditional SPPS, LPPS is poised to become the new standard in peptide synthesis. As the demand for peptide-based therapies continues to grow, Cambrex’s innovative technology is well-positioned to meet the industry’s needs for efficient, sustainable, and high-quality peptide synthesis.
About Cambrex
Cambrex is a global contract development and manufacturing organization (CDMO) providing drug substance development and manufacturing services across the entire drug lifecycle, as well as comprehensive analytical and IND-related services. With more than 40 years of experience and a team of 2,000 professionals serving global customers in North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state research, materials characterization, and highly active APIs.
